New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights article on managing adverse effects of obesity medications. Related Content:

• Managing Adverse Effects of Incretin-Based Medications for Obesity

-----------------------------------

JAMA Editors' Summary